Literature DB >> 9474479

Anti-gram-positive agents. What we have and what we would like.

R N Grüneberg1.   

Abstract

The usefulness of many anti-Gram-positive antibiotics is being compromised by the spread of antibiotic resistance in bacteria. The most reliable agents for serious infections are the glycopeptide agents vancomycin and teicoplanin. The appropriate maintenance dosage for teicoplanin in serious infections is 6 mg/kg/day, i.e. usually 400 mg/day. There are 3 exceptions for which the daily maintenance dosage should be 12 mg/kg/day and these are intravenous drug abusers, septic arthritis (but not osteomyelitis), and Staphylococcus aureus endocarditis treated with teicoplanin monotherapy. When teicoplanin is given at these doses, it achieves clinical and bacteriological results that are equivalent to those obtained with vancomycin, irrespective of pathogen or type of infection. The toxicity profile favours teicoplanin over vancomycin, especially when other, potentially toxic, drugs are coadministered. Teicoplanin also has an advantage in terms of ease and convenience of administration, which, together with its lack of need for routine blood level monitoring, facilitates its use outside hospital. New agents hold some promise for the future; however, oral agents, if developed, could present the risk of being overused, which might compromise their long term utility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9474479     DOI: 10.2165/00003495-199700546-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  A critical review of the in-vitro activity of teicoplanin.

Authors:  R C Spencer; R Goering
Journal:  Int J Antimicrob Agents       Date:  1995-05       Impact factor: 5.283

2.  The causative organisms of septicaemia and their epidemiology.

Authors:  S J Eykyn; W R Gransden; I Phillips
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

Review 3.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.

Authors:  M Michel; L Gutmann
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

4.  Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.

Authors:  C Y Liu; W S Lee; C P Fung; N C Cheng; C L Liu; S P Yang; S L Chen
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

5.  Methicillin-resistant Staphylococcus aureus in Europe.

Authors:  A Voss; D Milatovic; C Wallrauch-Schwarz; V T Rosdahl; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

6.  4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin.

Authors:  M Venditti; V Gelfusa; P Serra; C Brandimarte; A Micozzi; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

7.  Teicoplanin in home therapy of the terminally ill child.

Authors:  L M Ball; S Siddal; H van Saenen
Journal:  Eur J Haematol Suppl       Date:  1993

8.  Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis.

Authors:  W Graninger; C Wenisch; E Wiesinger; M Menschik; J Karimi; E Presterl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

9.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

Authors:  W C Noble; Z Virani; R G Cree
Journal:  FEMS Microbiol Lett       Date:  1992-06-01       Impact factor: 2.742

10.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Authors:  R N Jones; H S Sader; M E Erwin; S C Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1995-02       Impact factor: 2.803

View more
  2 in total

1.  Management of serious staphylococcal infections in the outpatient setting.

Authors:  W Graninger; E Presterl; C Wenisch; E Schwameis; S Breyer; T Vukovich
Journal:  Drugs       Date:  1997       Impact factor: 9.546

2.  Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults.

Authors:  S Esposito; S Leone; M Bassetti; S Borrè; F Leoncini; E Meani; M Venditti; F Mazzotta
Journal:  Infection       Date:  2009-11-10       Impact factor: 7.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.